IMPORTANT INFORMATION
All requests for funding should be submitted at least 60 days prior to the planned activity date. Submissions with shorter lead times are subject to denial if reviews cannot be completed.
For Educational Grants:
Before you begin the application process, please review the "Guidelines" section for the most current requirements and general guidance on new requests for funding.
For Charitable Contributions:
This site is for educational grant applications only. If you are requesting support for a charitable event (e.g. gala, dinner, run, walk, fundraiser) and are a 501(c) 3 organization click here.
HISTORY
Centocor Ortho Biotech Inc. was created in 2008 by bringing together two pioneering and well-established Johnson & Johnson organizations, Centocor, Inc. and Ortho Biotech Inc. Both companies had a long history of providing solutions that extend and improve human health.
Centocor was founded in 1979 and focused initially on the development of diagnostic assays using monoclonal antibody technology. In subsequent years, the company boldly ventured into the development of therapeutic drugs, including REMICADE ® (infliximab) for a number of immune disorders. In 1999, Johnson & Johnson acquired Centocor and gained access to the company's monoclonal antibody technology, expertise and growth potential.
Johnson & Johnson established Ortho Biotech in 1990, making it the first biotechnology subsidiary of a major healthcare company. From the beginning, Ortho Biotech dedicated its resources and resourcefulness to providing products and services to help improve the lives of patients with cancer and with anemia due to multiple causes. In addition, the company has been recognized for its treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses.
Today, Centocor Ortho Biotech Inc. harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech Inc. is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and healthcare professionals have access to the latest treatment information, support services and quality care.
